SCHEMBL330488

SCHEMBL330488

COc1[c]cc(-c2ccccc2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 3/20 0.38
MAPT P10636 3/20 0.38
PDE4A P27815 2/20 0.38
PDE4C Q08493 2/20 0.38
PDE4D Q08499 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
TSHR P16473 1/20 0.38
ATM Q13315 1/20 0.38
ALDH1A1 P00352 5/20 0.38
CA4 P22748 1/20 0.36
KDM4E B2RXH2 4/20 0.35
TDP1 Q9NUW8 2/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 1/20 0.35
LMNA P02545 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
HPGD P15428 1/20 0.35
MAPK1 P28482 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4820299 0.83 ESR2 (0.48) MAPTKDM4ETDP1NPC1RAB9A
SCHEMBL29207844 0.82 ALDH1A1 (0.38) MAPTMEN1KMT2AALDH1A1NPC1
SCHEMBL27342664 0.82 NPC1 (0.37) NPC1RAB9ABCL2L1
SCHEMBL4905103 0.81 PTGS1 (0.38) MAPTMEN1KMT2ATSHRLMNA
SCHEMBL1181147 0.80 CYP1A1 (0.48) CYP1A2CYP3A4GAA
SCHEMBL3698804 0.79 KIF11 (0.42) MAPTKMT2ATSHRALDH1A1KDM4E
SCHEMBL25282327 0.77 HRH3 (0.50) TAAR1
SCHEMBL28859758 0.77 PTPRC (0.46) ALDH1A1CA4KDM4ELMNAGAA
SCHEMBL4831668 0.76 PTGS2 (0.44) SMN1; SMN2
SCHEMBL3541755 0.75 KIF11 (0.41) ALDH1A1TDP1MAPK1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8039474-B2 2,3,4,9-tetrahydro-1H-carbazole derivatives as CRTH2 receptor antagonists ACTELION PHARMACEUTICAL LTD. (CH) 2011-10-18 US claimed
EP-1833791-B1 2,3,4,9-TETRAHYDRO-1H-CARBAZOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2011-08-03 EP claimed
EP-1855696-B1 9A-CARBAMOYL-Y-AMINOPROPYL- AND 9A-THIOCARBAMOYL-Y-AMINOPROPYL-AZALIDES WITH ANTIMALARIAL ACTIVITY GLAXOSMITHKLINE ZAGREB (HR) 2010-04-28 EP claimed
US-7626030-B2 Compounds and methods of use AMGEN INC. (US) 2009-12-01 US claimed
US-20090270414-A1 2,3,4,9- TETRAHYDRO-1H-CARBAZOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD. (CH) 2009-10-29 US claimed
US-7435823-B2 Compounds and methods of use AMGEN INC. (US) 2008-10-14 US claimed
US-20080200404-A1 Novel Antimalarial 9A-Carbamoyl-Aminoalkyl and 9A-Thiocarbamoyl-Aminoalkyl Azalides GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB D.O.O (HR) 2008-08-21 US claimed
EP-1855696-A2 9A-CARBAMOYL-Y-AMINOPROPYL- AND 9A-THIOCARBAMOYL-Y-AMINOPROPYL-AZALIDES WITH ANTIMALARIAL ACTIVITY GlaxoSmithKline istrazivacki centar Zagreb d.o.o. (HR) 2007-11-21 EP claimed
EP-1833791-A2 2,3,4,9-TETRAHYDRO-1H-CARBAZOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS Actelion Pharmaceuticals Ltd. (CH) 2007-09-19 EP claimed
JP-2007518824-A 2007-07-12 JP claimed
WO-2005073224-A2 QUINOLINE QUINAZOLINE PYRIDINE AND PYRIMIDINE COUNDS AND THEIR USE IN THE TREATMENT OF INFLAMMATION ANGIOGENESIS AND CANCER AMGEN INC (US) 2005-08-11 WO claimed
WO-2005070891-A2 COMPOUNDS AND METHODS OF USE AMGEN INC (US) 2005-08-04 WO claimed
EP-1406863-A4 INSECTICIDAL BIPHENYLTHIOHYDRAZIDES BASF AG (DE) 2005-06-15 EP claimed
EP-1406863-A1 INSECTICIDAL BIPHENYLTHIOHYDRAZIDES BASF AKTIENGESELLSCHAFT (DE) 2004-04-14 EP claimed
WO-2002098841-A1 INSECTICIDAL BIPHENYLTHIOHYDRAZIDES BASF AKTIENGESELLSCHAFT (DE) 2002-12-12 WO claimed
WO-2002064558-A2 OXAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS CYTOKINE INHIBITORS SANKYO COMPANY, LIMITED (JP) 2002-08-22 WO claimed
US-6436961-B1 SUBSTANCE P RECEPTOR ANTAGONIST; 2-PHENYL-3-BENZYLAMINOPIPERIDINES PFIZER INC 2002-08-20 US claimed
EP-1066257-A2 HETEROCYLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE Sugen, Inc. (US) 2001-01-10 EP claimed
WO-1999048868-A9 HETEROCYCLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE SUGEN INC (US) 2000-04-20 WO claimed
WO-1999048868-A2 HETEROCYCLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE SUGEN, INC. (US) 1999-09-30 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270414-A1 2,3,4,9- TETRAHYDRO-1H-CARBAZOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS HRH2, CRHR2, GRK2 PDE4B 486/4885MAPT 4385/4885PDE4A 680/4885
US-20080200404-A1 Novel Antimalarial 9A-Carbamoyl-Aminoalkyl and 9A-Thiocarbamoyl-Aminoalkyl Azalides DCTD, DHODH, DHRS9 PDE4B 305/4885MAPT 4458/4885PDE4A 424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.